comprehensive -WSS

comprehensive

author：Wikipedia 2025-09-29 16:45:43 - browse：3722

Becton Dickinson plans to pay $4.2 billion for Edwards Lifesciences’ critical care business, which sells technology that monitors the heart conditions of critically ill patients.

Edwards had told investors in December 2023 that it planned to spin off the business in order to focus more sharply on addressing structural defects in the heart. BD, meanwhile, wants to increase its monitoring presence in hospitals. In a statement announcing the acquisition, the company touted the “advanced AI algorithms” used in Edwards’ monitors.

BD CEO Tom Polen said in a statement that the acquisition will bolster BD’s portfolio of “AI-enabled clinical decision tools” and digital health products in general.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： First Opinion Podcast: How to protect health care in times of war

WSS

Special counsel alerts court to Trump’s social media post

Pharma needs to include young adults in clinical research

Rock icon Freddie Mercury pre

Chimpanzees, like humans and whales, get menopause: Study

Slain Parkland victim's father speaks out following reenactment

Climate activists disrupt London Pride march to protest corporate sponsorship

hotspot

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

hotspot

BioMarin wins approval for gene therapy to treat hemophilia A

Prosecutors seek bail revocation for FTX founder Sam Bankman

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Chimpanzees, like humans and whales, get menopause: Study

How to save PrEP access — and even expand it

WHO may add ‘noma' to its list of neglected tropical diseases

Anesthesiologist group: stop taking Ozempic before surgery

Readout Newsletter: What happened with Sarepta's Duchenne data

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Teen charged with murder as hate crime in killing of NYC dancer O'Shae Sibley: Sources

explore

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Pediatricians' group reaffirms support for gender

Biden's order seeks to regulate AI risk without stifling innovation

Jailed Russian opposition leader Alexey Navalny gets 19 more years in prison

The FDA weighs the risks of candy

New company forms to vet health AI models, root out weaknesses

knowledge

focus

hotspot

leisure time